Press Releases

BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to […]

BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions Read More »

BioCina Expands Partnership with GPN Vaccines

Adelaide, South Australia, November 6, 2023, BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such

BioCina Expands Partnership with GPN Vaccines Read More »

GenomeFrontier Selects BioCina to Manufacture Minicircle and Plasmid DNA for Their CAR-T Cell Therapy Product

ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T)

GenomeFrontier Selects BioCina to Manufacture Minicircle and Plasmid DNA for Their CAR-T Cell Therapy Product Read More »

BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines

MIAMI and ADELAIDE, Australia, April 27, 2023 /PRNewswire/ — BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $5.0m AUD grant under the Federal Government’s Medical Research Future Fund (MRFF) Grants scheme to fund work with its industry partners to develop enabling technologies for manufacture

BioCina awarded Grants to develop enabling technologies for manufacture of precision mRNA vaccines Read More »

Mark W. Womack Joins BioCina as CEO

(MIAMI and ADELAIDE March 14, 2023) BioCina, a leading contract development and manufacturing organization (CDMO) has appointed Mark W. Womack as CEO. Womack will be responsible for the continued growth, commercial strategy and organizational culture of BioCina. This follows the appointment of founding CEO, Ian Wisenberg, to Executive Chairman of BioCina Board of Directors. “Over

Mark W. Womack Joins BioCina as CEO Read More »

BioCina awarded Grant to advance RNA vaccines and therapeutics

(SAN DIEGO and ADELAIDE April 5, 2022) BioCina, a leading contract development and manufacturing organization (CDMO) is pleased to announce that it has been awarded a $3.0m AUD grant under the Federal Government’s Cooperative Research Centres Projects (CRC-P) Grants scheme to fund work with its industry partners to further develop RNA vaccines and therapeutics. The

BioCina awarded Grant to advance RNA vaccines and therapeutics Read More »

Rick Hancock named as Board Chairman for BioCina

(SAN DIEGO and ADELAIDE January 26,2022) BioCina, a leading contract development and manufacturing organization (CDMO) announces the appointment of Rick Hancock, Chairman of the Board. Hancock, with over 35 years of experience in life sciences, has held various board, executive and operational positions, developing expertise in cGMP manufacturing including plasmids, regulatory affairs, R & D,

Rick Hancock named as Board Chairman for BioCina Read More »

BioCina officially opens full-service CDMO in Adelaide, Australia, including mRNA and pDNA GMP manufacturing

(SAN DIEGO and ADELAIDE, November 30, 2021) BioCina, a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines announces the official opening of its new biologics manufacturing facility in Adelaide, Australia. The official opening for the research, development and manufacturing biologic plant in Adelaide

BioCina officially opens full-service CDMO in Adelaide, Australia, including mRNA and pDNA GMP manufacturing Read More »

BioCina expands into full-service CDMO with full control of Pfizer manufacturing facility in Adelaide, Australia

(SAN DIEGO and ADELAIDE, October 5, 2021) BioCina, a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of microbial-based therapeutics and mRNA vaccines announces the full and final transition from Hospira Adelaide Pty Ltd., an affiliate of Pfizer Inc., of its biologics manufacturing facility, colleagues and operations in Adelaide,

BioCina expands into full-service CDMO with full control of Pfizer manufacturing facility in Adelaide, Australia Read More »